Proton therapy for atypical meningiomas

Mark W. McDonald, David A. Plankenhorn, Kevin P. McMullen, Mark A. Henderson, Edward Dropcho, Mitesh V. Shah, Aaron Cohen-Gadol

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We report clinical outcomes of proton therapy in patients with World Health Organization grade 2 (atypical) meningiomas. Between 2005 and 2013, 22 patients with atypical meningiomas were treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after surgery (n = 12) or for recurrence or progression of residual tumor (n = 10). Six patients had presumed radiation-induced meningiomas, but none had received prior radiotherapy for their meningioma. The median follow-up time after radiation was 39 months (range 7–104) and all patients remain alive at last follow-up. The 5-year estimate of local control was 71.1 % (95 % CI 49.3–92.9 %). The 5-year estimate of local control was 87.5 % following a radiation dose >60 Gy (RBE), compared to 50.0 % for ≤60 Gy (RBE) (p = 0.038). The 5-year estimate of neuraxis dissemination was 5 % (95 % CI 0–14.6 %) and 6.2 % (95 % CI 0–18.2 %) for metastases outside of the central nervous system. Radiation necrosis was observed in one patient with a history of prior cranial irradiation. Fractionated proton therapy was associated with favorable tumor control rates for grade 2 meningiomas. Prospective studies are needed to define the optimal radiation dose for high-grade meningiomas.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalJournal of Neuro-Oncology
Volume123
Issue number1
DOIs
StatePublished - May 26 2015

Fingerprint

Proton Therapy
Meningioma
Radiation
Cranial Irradiation
Residual Neoplasm
Necrosis
Radiotherapy
Central Nervous System
Prospective Studies
Neoplasm Metastasis
Recurrence
Neoplasms

Keywords

  • Atypical
  • Meningioma
  • Proton therapy
  • Radiation

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

McDonald, M. W., Plankenhorn, D. A., McMullen, K. P., Henderson, M. A., Dropcho, E., Shah, M. V., & Cohen-Gadol, A. (2015). Proton therapy for atypical meningiomas. Journal of Neuro-Oncology, 123(1), 123-128. https://doi.org/10.1007/s11060-015-1770-9

Proton therapy for atypical meningiomas. / McDonald, Mark W.; Plankenhorn, David A.; McMullen, Kevin P.; Henderson, Mark A.; Dropcho, Edward; Shah, Mitesh V.; Cohen-Gadol, Aaron.

In: Journal of Neuro-Oncology, Vol. 123, No. 1, 26.05.2015, p. 123-128.

Research output: Contribution to journalArticle

McDonald, MW, Plankenhorn, DA, McMullen, KP, Henderson, MA, Dropcho, E, Shah, MV & Cohen-Gadol, A 2015, 'Proton therapy for atypical meningiomas', Journal of Neuro-Oncology, vol. 123, no. 1, pp. 123-128. https://doi.org/10.1007/s11060-015-1770-9
McDonald MW, Plankenhorn DA, McMullen KP, Henderson MA, Dropcho E, Shah MV et al. Proton therapy for atypical meningiomas. Journal of Neuro-Oncology. 2015 May 26;123(1):123-128. https://doi.org/10.1007/s11060-015-1770-9
McDonald, Mark W. ; Plankenhorn, David A. ; McMullen, Kevin P. ; Henderson, Mark A. ; Dropcho, Edward ; Shah, Mitesh V. ; Cohen-Gadol, Aaron. / Proton therapy for atypical meningiomas. In: Journal of Neuro-Oncology. 2015 ; Vol. 123, No. 1. pp. 123-128.
@article{d45113987d3e47969d983d1cd4d600ff,
title = "Proton therapy for atypical meningiomas",
abstract = "We report clinical outcomes of proton therapy in patients with World Health Organization grade 2 (atypical) meningiomas. Between 2005 and 2013, 22 patients with atypical meningiomas were treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after surgery (n = 12) or for recurrence or progression of residual tumor (n = 10). Six patients had presumed radiation-induced meningiomas, but none had received prior radiotherapy for their meningioma. The median follow-up time after radiation was 39 months (range 7–104) and all patients remain alive at last follow-up. The 5-year estimate of local control was 71.1 {\%} (95 {\%} CI 49.3–92.9 {\%}). The 5-year estimate of local control was 87.5 {\%} following a radiation dose >60 Gy (RBE), compared to 50.0 {\%} for ≤60 Gy (RBE) (p = 0.038). The 5-year estimate of neuraxis dissemination was 5 {\%} (95 {\%} CI 0–14.6 {\%}) and 6.2 {\%} (95 {\%} CI 0–18.2 {\%}) for metastases outside of the central nervous system. Radiation necrosis was observed in one patient with a history of prior cranial irradiation. Fractionated proton therapy was associated with favorable tumor control rates for grade 2 meningiomas. Prospective studies are needed to define the optimal radiation dose for high-grade meningiomas.",
keywords = "Atypical, Meningioma, Proton therapy, Radiation",
author = "McDonald, {Mark W.} and Plankenhorn, {David A.} and McMullen, {Kevin P.} and Henderson, {Mark A.} and Edward Dropcho and Shah, {Mitesh V.} and Aaron Cohen-Gadol",
year = "2015",
month = "5",
day = "26",
doi = "10.1007/s11060-015-1770-9",
language = "English",
volume = "123",
pages = "123--128",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Proton therapy for atypical meningiomas

AU - McDonald, Mark W.

AU - Plankenhorn, David A.

AU - McMullen, Kevin P.

AU - Henderson, Mark A.

AU - Dropcho, Edward

AU - Shah, Mitesh V.

AU - Cohen-Gadol, Aaron

PY - 2015/5/26

Y1 - 2015/5/26

N2 - We report clinical outcomes of proton therapy in patients with World Health Organization grade 2 (atypical) meningiomas. Between 2005 and 2013, 22 patients with atypical meningiomas were treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after surgery (n = 12) or for recurrence or progression of residual tumor (n = 10). Six patients had presumed radiation-induced meningiomas, but none had received prior radiotherapy for their meningioma. The median follow-up time after radiation was 39 months (range 7–104) and all patients remain alive at last follow-up. The 5-year estimate of local control was 71.1 % (95 % CI 49.3–92.9 %). The 5-year estimate of local control was 87.5 % following a radiation dose >60 Gy (RBE), compared to 50.0 % for ≤60 Gy (RBE) (p = 0.038). The 5-year estimate of neuraxis dissemination was 5 % (95 % CI 0–14.6 %) and 6.2 % (95 % CI 0–18.2 %) for metastases outside of the central nervous system. Radiation necrosis was observed in one patient with a history of prior cranial irradiation. Fractionated proton therapy was associated with favorable tumor control rates for grade 2 meningiomas. Prospective studies are needed to define the optimal radiation dose for high-grade meningiomas.

AB - We report clinical outcomes of proton therapy in patients with World Health Organization grade 2 (atypical) meningiomas. Between 2005 and 2013, 22 patients with atypical meningiomas were treated to a median dose of 63 Gy (RBE) using proton therapy, as an adjuvant therapy after surgery (n = 12) or for recurrence or progression of residual tumor (n = 10). Six patients had presumed radiation-induced meningiomas, but none had received prior radiotherapy for their meningioma. The median follow-up time after radiation was 39 months (range 7–104) and all patients remain alive at last follow-up. The 5-year estimate of local control was 71.1 % (95 % CI 49.3–92.9 %). The 5-year estimate of local control was 87.5 % following a radiation dose >60 Gy (RBE), compared to 50.0 % for ≤60 Gy (RBE) (p = 0.038). The 5-year estimate of neuraxis dissemination was 5 % (95 % CI 0–14.6 %) and 6.2 % (95 % CI 0–18.2 %) for metastases outside of the central nervous system. Radiation necrosis was observed in one patient with a history of prior cranial irradiation. Fractionated proton therapy was associated with favorable tumor control rates for grade 2 meningiomas. Prospective studies are needed to define the optimal radiation dose for high-grade meningiomas.

KW - Atypical

KW - Meningioma

KW - Proton therapy

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=84930212505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930212505&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1770-9

DO - 10.1007/s11060-015-1770-9

M3 - Article

C2 - 25859843

AN - SCOPUS:84930212505

VL - 123

SP - 123

EP - 128

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -